BerGenBio ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.
BerGenBio ASA (BRRGF) - Total Assets
Latest total assets as of June 2025: $86.75 Million USD
Based on the latest financial reports, BerGenBio ASA (BRRGF) holds total assets worth $86.75 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BerGenBio ASA - Total Assets Trend (2014–2024)
This chart illustrates how BerGenBio ASA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BerGenBio ASA - Asset Composition Analysis
Current Asset Composition (December 2024)
BerGenBio ASA's total assets of $86.75 Million consist of 99.2% current assets and 0.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 90.0% |
| Accounts Receivable | $679.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how BerGenBio ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BerGenBio ASA's current assets represent 99.2% of total assets in 2024, a decrease from 111.4% in 2014.
- Cash Position: Cash and equivalents constituted 90.0% of total assets in 2024, down from 103.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
BerGenBio ASA Competitors by Total Assets
Key competitors of BerGenBio ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
BerGenBio ASA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BerGenBio ASA generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BerGenBio ASA is currently not profitable relative to its asset base.
BerGenBio ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.39 | 5.05 | 15.04 |
| Quick Ratio | 4.39 | 5.05 | 15.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $66.93 Million | $ 175.04 Million | $ 741.96 Million |
BerGenBio ASA - Advanced Valuation Insights
This section examines the relationship between BerGenBio ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.40 |
| Latest Market Cap to Assets Ratio | 0.95 |
| Asset Growth Rate (YoY) | -10.6% |
| Total Assets | $155.80 Million |
| Market Capitalization | $147.25 Million USD |
Valuation Analysis
Near Book Valuation: The market values BerGenBio ASA's assets close to their book value ( 0.95x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: BerGenBio ASA's assets decreased by 10.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BerGenBio ASA (2014–2024)
The table below shows the annual total assets of BerGenBio ASA from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $155.80 Million | -10.63% |
| 2023-12-31 | $174.34 Million | +4.58% |
| 2022-12-31 | $166.71 Million | -62.97% |
| 2021-12-31 | $450.24 Million | -39.01% |
| 2020-12-31 | $738.20 Million | +173.03% |
| 2019-12-31 | $270.38 Million | -28.63% |
| 2018-12-31 | $378.83 Million | -1.43% |
| 2017-12-31 | $384.34 Million | +120.20% |
| 2016-12-31 | $174.54 Million | +111.84% |
| 2015-12-31 | $82.39 Million | -32.25% |
| 2014-12-31 | $121.61 Million | -- |